PATENT CLAIM ANALYSIS

Application Number: 16146965
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["435", "455000"]

Abstract:
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Claim (Index 1):
A method for producing insulin in response to a hyperglycemic environment comprising contacting said environment with a population of human transgenic beta cells, wherein each transgenic human beta cell expresses or overexpresses a human fugetactic agent in an amount sufficient to render said beta cell resistant to human immune cells, wherein said beta cell is capable of expressing insulin and incapable of cell division.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.33333
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15813917', '15019449', '11667410', '15840930', '15590587']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5438674080383322
- 35 USC 102 Novelty (BERT): 0.5039466283816981
- Combined Prediction Score: 0.5398753300726689
- Mean Citation Score: 201.67368
- Max Citation Score: 209.61426
- Similarity Product: 121.07858196266056

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test